跳至主要内容
临床试验/NCT06961682
NCT06961682尚未招募不适用

Effectiveness of MD on Patient With MetS to Control Hypertension, Diabetes ,Obesity and Dyslipidemia in Patients Attending Assiut University Hospital

Assiut University0 个研究点目标入组 170 人开始时间: 2025年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
170
主要终点
Assessment the effectiveness of MD on hypertensive MetS patients

研究概览

简要总结

The metabolic syndrome (MetS), is a complicated condition linked to coronary artery disease.This group includes visceral obesity (abdominal or android type obesity), insulin resistance (IR), hypertension, and dyslipidaemia.The global prevalence of MetS is estimated to be about one-quarter of the world population or over a billion global citizens .A high MetS prevalence of 55% was found in Egyptians, 85.6% among diabetics, and 76.6% among hypertensive patients .People can modify their diet, physical activity, decrease smoking habits to lower their chance of developing MetS. Frequent exercise can lower blood pressure while increasing insulin sensitivity, lipolysis, and energy expenditure. It has the ability to improve blood lipid parameters .Diet is one of the most important tools available to improve MetS. However, the diet for the prevention and treatment of MetS remains unspecified beyond weight control and reduction in total calories. Several evidences show that it should generally be low in saturated fats, trans fats, cholesterol, sodium and simple sugars .The adherence to the Mediterranean Diet(MD) brings up two positive features, firstly the activity levels are increased and secondly the environmental impact becomes self-rewarding. The more the MD is favoured, the more the self-productivity is achieved resulting in a stronger life style adaptation .MD causes reduction of CVD incidence and outcomes decreases BP (systolic and diastolic) , inverses association with mortality,improvements in dyslexia, decreases incidence of T2DM.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion criteria:
  • All people diagnosed as metabolic syndrome
  • (Hypertension(systolic BP≥130 or Diastolic BP ≥85)
  • prediabetes fasting plasma glucose(100-125),oral glucose tolerance test(140-199)Hba1c(5.7-6.4)ADA
  • Diabetes, fasting>125, oral glucose tolerance test>200, Hba1c≥6.5 ADA .
  • Hyperlipidaemia(TG≥150 mg\dl-HDL<40 in male and <50 in female) [12]
  • Obesity(waist circumference ≥102cm in male and ≥88cm in female) [12]

排除标准

  • Type 1 diabetes
  • Patients with renal or advanced liver disease(Failure)
  • Oral contraceptives, psychiatric, neurologic medications and steroid therapy
  • Patients with heart failure and presence of stent
  • Endocrine disease (Thyroid disease especially hypothyroidism-Cushing disease)

结局指标

主要结局

Assessment the effectiveness of MD on hypertensive MetS patients

时间窗: 6 months

by regular measuring to blood pressure mmHg before and after the MD

Assessment the effectiveness of MD on diabetic MetS patients

时间窗: 6 months

by measuring Hga1c before and after the MD

Assessment the effectiveness of MD on dyslipidemic MetS patients

时间窗: 6 months

by measuring lipid profile HDL, LDL, TG

Assessment the effectiveness of MD on obese MetS patients

时间窗: 6 months

by measuring weight in kg and height in meters to calculate BMI which equal weight\\height square meters before and after MD at 3 and 6 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Amira Gaber Osman

Assistant lecturer

Assiut University

相似试验

Effectiveness of MD on MetS Patients | 临床试验